Francesco Saraceni

12PUBLICATIONS
59CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)HaematologyGene and molecular therapyCardiovascular medicine and haematology not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Jul 02, 2026
Early software-assisted response predicts survival in a prospective cohort of 258 newly diagnosed cGvHD patients.

|Jun 24, 2026
A phase II multicenter prospective study to evaluate the safety and efficacy of myeloablative-dose treosulfan plus fludarabine (FT14) conditioning regimen in allogeneic hematopoietic stem cell transplantation for AML patients aged 40-65 in first complete remission.

|Sep 25, 2023
Thiotepa-busulfan-fludarabine Compared to Treosulfan-based Conditioning for Haploidentical Transplant With Posttransplant Cyclophosphamide in Patients With Acute Myeloid Leukemia in Remission: A Study From the Acute Leukemia Working Party of the EBMT.

Francesco Saraceni, Myriam Labopin, Anna M Raiola

|Feb 25, 2022
Autologous Stem Cell Transplantation in Multiple Myeloma: Where Are We and Where Do We Want to Go?

Sonia Morè, Laura Corvatta, Valentina Maria Manieri

|Nov 26, 2020
Allogeneic stem cell transplant in patients with acute myeloid leukemia and karnofsky performance status score less than or equal to 80%: A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation (EBMT).

Francesco Saraceni, Myriam Labopin, Edouard Forcade

|Jul 07, 2020
Severe COVID-19 in a patient with chronic graft-versus-host disease after hematopoietic stem cell transplant successfully treated with ruxolitinib.

Francesco Saraceni, Ilaria Scortechini, Giorgia Mancini

Pageof 2

Frequent Collaborators

4 joint publications

Michele Malagola

3 joint publications

Francesca Patriarca

3 joint publications

Franca Fagioli

3 joint publications

Massimo Martino